BKHA

Business Context and Reporting Period

Company: Black Hawk Acquisition Corporation (Black Hawk)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended May 31, 2026
Business Status: Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands. The Company has not commenced operations and is seeking an initial business combination. It is classified as a shell company, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Income Decline: Net income for the three months ended May 31, 2026, was $88,929, a significant decrease from $520,542 in the same period in 2025. This is primarily due to a reduction in interest income earned on the Trust Account ($222,525 vs. $767,623) and the incurrence of interest expense ($24,381) related to new convertible notes, which was not present in the prior year.
• Trust Account Growth: The Trust Account balance increased from $23,827,149 (Nov 30, 2025) to $25,313,116 (May 31, 2026), driven by interest earnings and extension payments deposited to extend the business combination deadline.
• Liabilities Increase: Total current liabilities rose from $1,482,233 to $2,751,806. This increase is attributed to a rise in amounts due to the target company (Vesicor) from $575,000 to $1,300,801 and an increase in the convertible note balance with the related party from $595,369 to $1,232,366.
• Share Count Reduction: Following a shareholder vote in July 2025, approximately 4.78 million public shares were redeemed, reducing the outstanding public share count from 6.9 million to 2.12 million.

Outlook, Risks, and Management Commentary

• Business Combination Status: The Company has entered into a Business Combination Agreement with Vesicor Therapeutics, Inc., valued at a pre-money equity value of $70 million. The transaction is subject to regulatory and shareholder approvals. The Company filed Amendment No. 3 to its Form S-4 on March 4, 2026.
• Extension of Deadline: Shareholders approved an extension proposal allowing the Company to extend the business combination deadline monthly through December 22, 2026, contingent on depositing $150,000 per month into the Trust Account.
• Going Concern: Management has determined that substantial doubt exists regarding the Company's ability to continue as a going concern due to a working capital deficit and the uncertainty of completing a business combination within the required timeframe.
• Nasdaq Delisting Risk: On March 31, 2026, the Company received a notice from Nasdaq stating its Market Value of Listed Securities (MVLS) fell below the $50 million minimum requirement. The Company has until September 28, 2026, to regain compliance or face potential delisting.
• Subsequent Event: On June 30, 2026, Vesicor forgave $1,015,988 in advances previously made to Black Hawk for extension payments and transaction expenses.

Investor Verification Checklist

• Delisting Compliance: Verify if the Company has regained Nasdaq compliance (MVLS > $50 million) by the September 28, 2026 deadline.
• Transaction Closing: Confirm the status of the Vesicor Therapeutics merger, specifically the approval of the Form S-4 and shareholder votes.
• Liquidity Sufficiency: Assess the Company's ability to fund the $150,000 monthly extension payments through December 2026 given the current cash balance of $11,583.
• Debt Forgiveness Impact: Review the implications of the June 30, 2026, debt forgiveness agreement on the Company's liabilities and the relationship with the target company.
• Extension Funding: Verify the source of funds for future extension payments, as the Company relies on related party convertible notes and target company contributions.